Takeda Pharmaceutical (TAK) Non Operating Interest Expenses (2017 - 2026)

Takeda Pharmaceutical has reported Non Operating Interest Expenses for 10 years, with the latest figure at -$400.6 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 45.91% year-over-year to -$400.6 million in Q2 2026; TTM through Jun 2026 was -$3.6 billion, a 21.67% decrease from a year earlier, with the FY2026 full-year figure at -$2.3 billion, down 65.34% from the prior year.
• Non Operating Interest Expenses was -$400.6 million for Q2 2026 at Takeda Pharmaceutical, up from -$683.6 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was -$198.5 million in Q1 2022, with the low at -$2.1 billion in Q3 2025.
• Average Non Operating Interest Expenses over 5 years is -$626.7 million, with a median of -$431.8 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Non Operating Interest Expenses jumped 72.08% in 2022, then sank 206.97% in 2023.
• Over 5 years, Non Operating Interest Expenses stood at -$564.5 million in 2022, then soared by 41.04% to -$332.8 million in 2023, then increased by 0.6% to -$330.9 million in 2024, then dropped by 6.64% to -$352.8 million in 2025, then slipped by 13.53% to -$400.6 million in 2026.
• The last three Non Operating Interest Expenses figures came in at -$400.6 million (Q2 2026), -$683.6 million (Q1 2026), and -$352.8 million (Q4 2025), per Business Quant data.